LZTS3

Across TCGA pan-cancer cohorts, LZTS3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LZTS3 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LZTS3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LZTS3 expression acts as an unfavorable survival marker.

OV, THYM, and LUSC are the cancer types where LZTS3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
STAD	OS	Median	All	0.138	0.669	<.001	12	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
LIHC	OS	Median	All	0.167	0.704	.041	3	view →
COAD	DFS	Median	III,IV	0.280	0.652	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LZTS3–OV (OS)

Open the OV breakdown →